Neuphoria Therapeutics is no longer a social-anxiety drug story. After the late-stage miss in the registrational anxiety study, the Burlington successor to Bionomics stripped the operating company down to cash, a single remaining employee, and a signed all-stock merger into London-listed Scancell Holdings. The equity now prices as a close-risk stub: holders swap a cash-backed microcap for a thin minority of a pre-revenue melanoma immunotherapy plus non-transferable contingent value rights on leftover partnered programs. The investment debate is whether that swap is better than sitting on the cash, not whether the internal candidate still has a development path.
The October miss ended the internal pipeline in practical terms. Management discontinued the social-anxiety program, paused the post-traumatic stress program, and accepted Scancell's statement that the buyer does not intend to develop the non-partnered assets after closing. What remains economically is the year-end cash pile, a Merck collaboration whose Alzheimer's candidate just failed an interim look, a Pfizer-linked KAT6 interest sitting inside a CRC trust, and an Australian research-tax credit that the contingent rights are written to capture. The market capitalization sits almost exactly on that cash.
Scancell is using the Nasdaq shell to fund a registrational melanoma study. Closing still requires both stockholder votes, an effective registration statement, a Nasdaq listing of new American depositary shares, at least seventy-five million of concurrent financing, and a ten million closing-cash test. The open question is whether the late-year close actually happens, and if it does, whether an eleven percent sliver of the melanoma program plus those contingent rights is worth more than the cash the board already holds.